A single short peptide can recognize two structurally different proteins by switching targets based on surrounding metal ions. That finding, from researchers at Saitama University in Japan, challenges existing assumptions about how small peptides interact with their molecular environments.
The peptide at the center of the study is called calmodulin-binding peptide, or CBP. It was already known to bind calmodulin, a regulatory protein involved in muscle contraction, neurotransmission, and cell-cycle control, when calcium ions are present. What the Saitama team discovered is that when sodium ions are present instead, CBP abandons calmodulin and binds to a completely different protein called human midkine.
According to a report by Phys.org, midkine is expressed at low levels in healthy adult tissue but becomes elevated in many cancers. That makes it both an emerging cancer biomarker and a potential therapeutic target.
The research team, led by Special Appointment Professor Naoto Nemoto and Professor Koji Matsuoka, tested CBP against multiple proteins including midkine, bovine serum albumin, GFP, and immunoglobulin G. They used surface plasmon resonance to measure binding and also applied AlphaFold 3 to predict how different metal ion conditions affect the structural relationship between CBP and its targets. They tested both the standard CBP and a mutant version with a single amino acid substitution.
The results were published in Biochemical and Biophysical Research Communications under the title "Calmodulin-binding peptide is a natural peptide aptamer that binds to human midkine in a metal ion-dependent manner."
Nemoto, the paper's corresponding author, described the finding as unexpected. "CBP has long been known as a peptide that binds to calmodulin. In this study, however, we found that in the presence of sodium ions, CBP recognizes human midkine, a protein with a completely different structure," he said.
"We were surprised to find that the same short peptide can recognize structurally distinct proteins under different ion conditions. This suggests that naturally occurring peptides may possess a previously unrecognized level of adaptability in molecular recognition," Nemoto added.
The implications reach beyond this one peptide. Short peptides that can selectively recognize disease-related proteins have attracted growing interest as tools for biosensors, diagnostic technologies, and drug discovery. The discovery that their target selection may be adjustable based on ionic environment adds a new variable to how researchers might design or evaluate such molecules.
Professor Matsuoka noted that midkine is not limited to cancer. The protein is also implicated in inflammation and neurodegenerative disorders, which broadens the potential relevance of CBP's newly discovered binding behavior.
